Partnerships Partnering News

04.22.2020

FoRx Therapeutics AG Raises EUR 10 Million Seed Round to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer

04.20.2020

Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15

03.17.2020

Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine

02.20.2020

Montis Biosciences launched with €8,4 million seed financing and a novel approach to immune-oncology

01.14.2020

Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets

01.13.2020

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.

01.13.2020

Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

12.23.2019

BioInvent announces selection of second target and extension of the research collaboration and license agreement with Pfizer Inc.

12.17.2019

Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders

12.10.2019

ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials

12.04.2019

ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

11.22.2019

CeMM enters into research collaboration on expanding the druggable proteome with Pfizer Inc.